Trial reportThe Journal of allergy and clinical immunology2008
Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Trial report in The Journal of allergy and clinical immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.Pulmonary medicine · 2019Pooled it
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2020Trial
- Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.Respiratory research · 2019Trial
- Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.The Journal of allergy and clinical immunology · 2010Trial
- Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin.The European respiratory journal · 2026Article
- Article
- Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Serum Type 2 Cytokine Levels Are Elevated in a Chronic Pulmonary Aspergillosis Subgroup with High Serum Total Immunoglobulin E Level.Journal of fungi (Basel, Switzerland) · 2025Article
- One SQ HEDGES DNA vector only dose produces durable hGLA or anti-SARS-CoV-2 mAb therapeutic serum protein levels.PloS one · 2025Article
- Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma.Frontiers in immunology · 2025Article
- IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.Mucosal immunology · 2024Article
- Review
- Helper T cell subsets: Development, function and clinical role in hypersensitivity reactions in the modern perspective.Heliyon · 2024Review
- Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives.Frontiers in immunology · 2023Review
- Interleukine-17 Modulates Neurogenesis and Behavior Following Exposure to Trauma in Mice.Cells · 2022Article
- Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients.Journal of personalized medicine · 2022Article
- OX40 Expression in Eosinophils Aggravates OVA-Induced Eosinophilic Gastroenteritis.Frontiers in immunology · 2022Article
- Beneficial effects of naringenin and morin on interleukin-5 and reactive oxygen species production in BALB/c mice with ovalbumin-induced asthma.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2021Article
- Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Tacrolimus (FK506) treatment protects allergen-, IL-5- and IL-13-induced mucosal eosinophilia.Immunology · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAnti-IL-5 might be a useful therapeutic agent for eosinophilic disorders, yet its immunologic consequences have not been well characterized.
objectiveWe sought to characterize the hematologic and immunologic effects of anti-IL-5 in human subjects.
methodsThe effects of 3-month infusions of mepolizumab were assessed in 25 patients with a variety of eosinophilic syndromes. Samples with increased IL-5 levels after therapy were analyzed by using size exclusion filtration. Immunoreactive IL-5 fraction and plasma samples were subsequently precipitated with saturating concentrations of protein A/G.
resultsTwenty-three patients responded to anti-IL-5 therapy with a decrease in blood eosinophil counts and a reduced percentage of CCR3(+) cells by 20- and 13-fold, respectively (P < .0001). Responsiveness was not related to the levels of baseline plasma IL-5 or the presence of FIP1L1-PDGFRA fusion gene. Persistently decreased blood eosinophilia remained for 3 months after final infusion in 76% of subjects. Therapy was associated with a large increase in blood IL-5 levels, likely because of a circulating IL-5/mepolizumab complex precipitated with protein A/G, a significant increase in eosinophil IL-5 receptor alpha expression, and increased percentage of CD4(+) and CD8(+) cells producing intracellular IL-5 (P < .05). Additionally, anti-IL-5 therapy decreased eotaxin-stimulated eosinophil shape change ex vivo.
conclusionsAnti-IL-5 therapy induces a dramatic and sustained decrease in blood eosinophilia (including CCR3(+) cells), decreased eosinophil activation, and increased circulating levels of IL-5 in a variety of eosinophilic disorders. Increased levels of IL-5 receptor alpha and lymphocyte IL-5 production after anti-IL-5 therapy suggest an endogenous IL-5 autoregulatory pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.